<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647125</url>
  </required_header>
  <id_info>
    <org_study_id>ESO-Shanghai3</org_study_id>
    <nct_id>NCT02647125</nct_id>
  </id_info>
  <brief_title>A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC</brief_title>
  <official_title>A Phase II Study of Comparing Huachansu Combination With Thoracic Radiotherapy Versus Radiotherapy Alone For Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This primary objective of the trial is to study whether the local control of Huachansu plus
      thoracic radiotherapy is better compared to thoracic radiotherapy alone for patients with
      esophageal squamous cell carcinoma. It's a phase II study, 134 patients are expected to be
      recruited into the trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-yr local control rate</measure>
    <time_frame>1 year</time_frame>
    <description>The outcome measure will be assessed by every 3-month follow-up examinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-yr local control rate</measure>
    <time_frame>3 years</time_frame>
    <description>The outcome measure will be assessed by every 3-month follow-up examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>The survival time from the day every patient enrolled to the day of death or the last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Huachansu Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive thoracic radiotherapy alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huachansu</intervention_name>
    <description>Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.</description>
    <arm_group_label>Huachansu Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>thoracic radiation</intervention_name>
    <description>A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.</description>
    <arm_group_label>Huachansu Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Joined the study voluntarily and signed informed consent form.

          2. Age ＞75 or age 18-75 who are intolerant of or reject intravenous chemotherapy.

          3. Both genders.

          4. Esophageal squamous cell carcinoma confirmed by pathology.

          5. Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a,TxN1M0-1a,TxNxM1a,
             AJCC 6th).

          6. No radiotherapy, chemotherapy or other treatments prior to enrollment.

          7. PS ECOG 0-2，wight loss&lt;30% during the latest 6 months.

          8. Life expectancy of more than 3 months.

          9. Hemoglobin（Hb）≥9 g/dL,WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L platelet count (Pt)
             ≥100x 109/L.Hepatic function: ALAT and ASAT &lt; 2.5 x ULN, TBIL&lt;1.5 x ULN.Renal
             function: creatinine &lt; 1.5 x ULN.

         10. No immuno-deficiency

         11. No heart diseases that need cardiac glycoside

         12. Use of an effective contraceptive for adults to prevent pregnancy.

        Exclusion Criteria:

          1. Complete esophageal obstruction.

          2. Deep esophageal ulcer.

          3. Esophageal perforation.

          4. Haematemesis.

          5. After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting
             therapy.

          6. Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in
             situ, who survived with no evidence disease for over 3 years.

          7. Pregnant or breast-feeding women or people during the birth-period who refused to take
             contraceptives.

          8. Drug addiction,Alcoholism or AIDS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kuaile Zhao, MD</last_name>
    <phone>+8618017312534</phone>
    <email>kuaile_z@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Liu, MD</last_name>
    <phone>+8618017317882</phone>
    <email>18017317882@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuaile Zhao, MD</last_name>
      <phone>+8618017312534</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kuai Le Zhao, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

